BPC-157 for Tendon Healing: Animal Studies Reviewed

Informational only. Not medical advice. BPC-157 is not FDA-approved for any clinical use. Most published evidence is animal or preclinical. Do not start, stop, or change any medical treatment based on what you read here. Speak with a licensed clinician before considering any peptide.

BPC-157, often called "Body Protection Compound," is a 15-amino-acid peptide first identified in human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s (STAT News, 2026). Rat studies report accelerated tendon-to-bone healing after BPC-157 administration (Krivic et al., 2006). The compound is not approved for human use by any regulator, and no peer-reviewed randomized controlled trial of BPC-157 has been published in humans for any indication (STAT News, 2026).

This article reviews the published tendon-healing animal studies, names the model and sample size, and flags what does and does not transfer to humans.

For the broader evidence base across tendon, muscle, gut, brain, and human safety, see our top 10 BPC-157 research studies review.

Does BPC-157 actually heal tendons in humans?

Unknown — no human trial has tested it. As of February 2026, zero peer-reviewed randomized controlled trials of BPC-157 for tendon healing have been published in humans (STAT News, 2026). The only human data is a handful of small uncontrolled case series — including a 16-patient knee-pain retrospective and a 12-patient bladder-injection study — all from one Florida clinic, none with placebo controls.

Animal data in rats is consistent: BPC-157 accelerates Achilles tendon-to-bone healing, restores biomechanical strength after quadriceps transection, and promotes tendon-explant fibroblast migration in vitro. None of those endpoints has been confirmed in any human RCT.

Current evidence-based options for tendinopathy — eccentric loading, progressive tendon loading protocols, and in some cases PRP — have human RCT data that BPC-157 does not.

How many tendon-healing studies of BPC-157 exist?

Roughly 10 peer-reviewed animal studies and zero human RCTs as of 2026. The 2025 systematic review by Vasireddi et al. screened 544 papers and identified 35 preclinical orthopedic studies plus one small human knee-pain case series — across all musculoskeletal applications, not just tendon (Vasireddi et al., 2025).

Of the most-cited tendon papers, 9 of 10 originate from the Sikiric lab in Zagreb. Over 100 of all published BPC-157 papers come from this single group — a concentration that independent reviewers flag as a replication concern (STAT News, 2026).

What's the largest BPC-157 tendon study?

Staresinic et al. (2006) — n=120 rats, quadriceps tendon transection. Researchers transected the quadriceps tendon, dosed BPC-157 systemically or topically, and measured biomechanical strength, function, and histology at day 14. Treated rats walked with less limp and tendons withstood higher pull force than controls (Staresinic et al., 2006).

For context: 120 rats is a large sample for an animal study, but the entire BPC-157 tendon literature has fewer total animals than a single Phase 1 human trial typically enrolls. The 2025 IV safety pilot (the only published human BPC-157 study to date) enrolled n=2 healthy adults (Lee et al., 2025).

The tendon-study summary table

<a id="study-table"></a>

#	Study (lead author, year)	Model	Sample	Primary outcome	Independent replication
1	Krivic et al., 2006	Rat Achilles detachment	n=80	Faster tendon-to-bone healing vs control	No (Zagreb)
2	Staresinic et al., 2006	Rat quadriceps transection	n=120	Biomechanical strength restored	No (Zagreb)
3	Krivic et al., 2008	Rat Achilles vs methylprednisolone	n=72	Better functional recovery than steroid arm	No (Zagreb)
4	Chang et al., 2011	Rat tendon explants + fibroblasts (in vitro)	Cell + tissue	Dose-dependent fibroblast migration	Yes (Chang lab, Taiwan)
5	Chang et al., 2014	Rat tendon fibroblasts	In vitro	GH receptor upregulation	Yes (Chang lab)
6	Cesarec et al., 2007	Rat muscle/myotendinous junction	Rat	Improved crush-injury recovery	No (Zagreb)
7	Krezic et al., 2021	Rat myotendinous junction	Multi-arm	Junction reformed by day 28-42	No (Zagreb)
8	Brcic et al., 2009	Rat tendon + muscle	Rat	VEGFR2 upregulated at injury site	No (Zagreb)
9	Vasireddi et al., 2025	Systematic review	36 studies	Zero human RCTs for tendon	Meta-review
10	Józwiak et al., 2025	Narrative review	—	Acknowledged absence of human approval	Meta-review

Why is most BPC-157 tendon research from one lab in Croatia?

The Sikiric lab at the University of Zagreb has produced the bulk of the BPC-157 literature since 1991 — including 9 of the 10 most-cited tendon studies. Independent replication is the gold standard in biomedical research. BPC-157 has had limited replication outside the original program (STAT News, 2026).

The notable exception in the tendon literature is the Chang lab in Taiwan, which produced the Journal of Applied Physiology tendon-explant paper (Chang et al., 2011) and the Molecules growth-hormone-receptor paper (Chang et al., 2014). These provide the only sustained independent tendon work to date.

Reviewers note the concentration of positive findings in one lab is itself a reason for cautious interpretation pending broader replication (STAT News, 2026).

What is BPC-157 and where does it come from?

BPC-157 is a pentadecapeptide — a chain of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was isolated in the early 1990s from human gastric juice by Predrag Sikiric and colleagues at the Department of Pharmacology, University of Zagreb (STAT News, 2026).

The first PubMed entry referencing BPC-157 dates to 1992. The "Body Protection Compound" name reflects its origin in the protective gastric environment, not a verified physiological role in humans. Whether the isolated fragment exists or acts in human tissue at meaningful concentrations remains scientifically open.

Researchers have proposed that the peptide's effects involve modulation of nitric oxide signaling, angiogenesis, and growth-factor pathways including VEGF. These remain hypotheses tested almost entirely in rodents.

How does BPC-157 affect tendon healing in animal models?

The headline tendon finding comes from Krivic, Anic, Seiwerth, Huljev, and Sikiric, who reported in the Journal of Orthopaedic Research that BPC-157 promoted Achilles tendon-to-bone healing in rats and counteracted corticosteroid-induced aggravation (Krivic et al., 2006).

A follow-up rat study compared BPC-157 against methylprednisolone in early functional recovery after Achilles tendon-to-bone transection, using 72 Wistar Albino male rats (Krivic et al., 2008). The BPC-157 group showed better functional recovery than the corticosteroid group.

A separate mechanistic paper reported that BPC-157 accelerated tendon explant outgrowth and increased migration of cultured rat Achilles tendon fibroblasts in a dose-dependent manner, while not directly affecting cell proliferation (Chang et al., 2011). Cell survival under H2O2 oxidative stress was also increased.

Proposed mechanism of action

The same Journal of Applied Physiology work pointed to activation of the FAK–paxillin pathway as a candidate mechanism for the fibroblast migration effect (Chang et al., 2011). FAK–paxillin signaling governs cell adhesion and movement during tissue repair.

A related rat study reported upregulation of growth hormone receptor expression in BPC-157-treated tendon fibroblasts (Chang et al., 2014). The authors suggested this could amplify endogenous growth-hormone signals during healing.

Tendons have limited vascular supply, which slows native healing. Promotion of angiogenesis and fibroblast migration in rodent models is the proposed reason BPC-157 might shorten that timeline, but this has not been confirmed in any human RCT.

Is BPC-157 banned or legal in 2026?

BPC-157 is not FDA-approved for any indication and is prohibited at all times in sport by WADA. In 2023, the FDA placed BPC-157 on the 503A Category 2 bulk drug substances list (Holt Law, 2024). The agency cited three concerns: potential immunogenicity, manufacturing impurity risk, and absence of human safety data.

In April 2026 the FDA removed BPC-157 from the explicit Category 2 prohibition, returning it to evaluative status pending Pharmacy Compounding Advisory Committee review — this is not an approval and compounding remains restricted (Newtropin, 2026).

WADA added BPC-157 to its Prohibited List in 2022 under category S0 (Non-Approved Substances). The 2025 Prohibited List continues to prohibit BPC-157 at all times — in and out of competition (WADA Prohibited List 2025). USADA states no Therapeutic Use Exemption is possible (USADA, 2024).

What are the safety concerns with BPC-157?

No long-term human safety data exists. Rat and mouse studies report low acute toxicity at the doses tested, but preclinical safety does not establish human safety, especially for chronic dosing or interactions with other drugs (STAT News, 2026).

The FDA's stated rationale for the 2023 Category 2 listing specifically called out the absence of human safety data — not animal harms, but the lack of evidence either way in people (Holt Law, 2024).

BPC-157's proposed mechanism includes promotion of angiogenesis and activation of VEGF pathways. These same pathways are exploited by solid tumors to grow blood supply and metastasize. Whether BPC-157 use could accelerate the growth of undetected cancers in humans is unstudied. This is one of the specific concerns sports-medicine reviewers cite when discouraging clinical use outside research settings (Vasireddi et al., 2025).

Consumers buying "research only" vials face unverified purity. The FDA has flagged injectable peptides sold this way for risks including immune reactions, cardiac events, and death.

Bottom line

The BPC-157 tendon evidence base is suggestive in rats and absent in humans. Across roughly 10 peer-reviewed animal studies, treated rats show faster tendon-to-bone healing and biomechanical recovery — but 9 of 10 originate from a single lab in Zagreb, and not one randomized controlled trial has tested the compound in humans for tendon injury.

If you are considering BPC-157 for a tendon injury, speak with a sports medicine physician. Recognize that current evidence-based options — eccentric loading, progressive tendon loading protocols, and in some cases PRP — have human RCT data that BPC-157 does not. WADA prohibits BPC-157 at all times for tested athletes, with no TUE pathway.

Related Reading

• Top 10 BPC-157 research studies (2026)
• BPC-157 for muscle healing: animal study review
• Compounded peptides vs research chemicals: 10 key differences (2026)
• Where to buy peptides legally in 2026

Frequently asked questions

Is BPC-157 approved for human use in 2026? No. BPC-157 has no FDA approval for any indication and remains under 503A bulks evaluation. The April 2026 FDA action removed it from explicit Category 2 prohibition but did not grant approval (Newtropin, 2026).

Are there any published human trials of BPC-157 for tendon healing? No. As of February 2026, zero peer-reviewed randomized controlled trials of BPC-157 in humans for any tendon indication have been published (STAT News, 2026). The only human data is small uncontrolled case series from one Florida clinic, none on tendon injury.

Why was BPC-157 banned by WADA? WADA added BPC-157 to the Prohibited List in 2022 under category S0 (Non-Approved Substances) because it has no current approval by any governmental health authority for human therapeutic use (USADA, 2024). The 2025 Prohibited List continues to ban it at all times.

What are the side effects of BPC-157? Animal studies have generally reported low acute toxicity, but there are no long-term human safety data from controlled trials. Theoretical concerns include angiogenesis-related effects on undetected tumors and unknown immunogenicity from impure compounded product (Holt Law, 2024).

Why is most BPC-157 tendon research from one lab? The Sikiric group at the University of Zagreb has published over 100 BPC-157 papers since 1991, including 9 of the 10 most-cited tendon studies. Independent replication outside that program is limited, which reviewers cite as a known concern in the evidence base.

---

Researched and drafted by Theo Park, an AI editorial persona at Peptide Front, against published sources. Reviewed by our editorial team.